Drug Price Trends for HEMORRHOIDAL MEDICATED

Average Pharmacy Cost for HEMORRHOIDAL MEDICATED

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
HEMORRHOIDAL MEDICATED 50% PAD	70000-0364-01	0.04290	EACH	2026-03-18
HEMORRHOIDAL MEDICATED 50% PAD	70000-0364-01	0.04176	EACH	2026-02-18
HEMORRHOIDAL MEDICATED 50% PAD	70000-0364-01	0.04066	EACH	2026-01-21
HEMORRHOIDAL MEDICATED 50% PAD	70000-0364-01	0.03935	EACH	2025-12-17
HEMORRHOIDAL MEDICATED 50% PAD	70000-0364-01	0.03867	EACH	2025-11-19

HEMORRHOIDAL MEDICATED Market Analysis and Price Projections

Last updated: February 18, 2026

The global market for hemorrhoidal medicated products is projected to reach $3.1 billion by 2030, with a compound annual growth rate (CAGR) of 4.2% from 2023. This growth is driven by an aging population, increasing prevalence of lifestyle-related factors contributing to hemorrhoids, and advancements in drug formulations.

What are the Key Market Segments for Hemorrhoidal Medicated Products?

The hemorrhoidal medicated market is segmented by product type, formulation, and distribution channel.

Product Type

• Over-the-Counter (OTC) Products: This segment dominates the market, accounting for approximately 75% of sales. OTC products include creams, ointments, suppositories, and wipes. They are readily accessible and address mild to moderate symptoms.
• Prescription Medications: This segment comprises a smaller but growing portion of the market, projected to increase at a CAGR of 5.5% from 2023 to 2030. Prescription options are typically for more severe cases and include corticosteroid treatments, anesthetics, and astringents.

Formulation

• Topical Creams and Ointments: These formulations represent the largest segment by volume, driven by ease of application and rapid localized relief. Key active ingredients include hydrocortisone, lidocaine, and phenylephrine hydrochloride.
• Suppositories: Suppositories are another significant formulation, particularly for internal hemorrhoids, providing targeted delivery of active agents.
• Wipes and Pads: Medicated wipes and pads offer a convenient and soothing option for hygiene and symptom management. These often contain witch hazel or other astringents.
• Oral Medications: While less common for direct hemorrhoid treatment, oral anti-inflammatories or stool softeners may be prescribed in conjunction with topical treatments.

Distribution Channel

• Pharmacies and Drug Stores: This is the primary distribution channel, encompassing both brick-and-mortar locations and online pharmacies. These channels accounted for over 60% of sales in 2022.
• Supermarkets and Hypermarkets: Growing in importance, these retailers offer a wide range of OTC hemorrhoidal products, contributing approximately 25% of market revenue.
• Online Retailers: E-commerce platforms are experiencing rapid growth, projected to increase their market share to 20% by 2030 due to convenience and wider product selection.

What is the Current Market Size and Projected Growth?

The global market for hemorrhoidal medicated products was valued at an estimated $2.5 billion in 2022. Projections indicate a steady expansion, reaching approximately $3.1 billion by 2030.

Year	Market Value (USD Billion)	CAGR (2023-2030)
2022	2.5	-
2023	2.6	4.2%
2024	2.7	4.2%
2025	2.8	4.2%
2026	2.9	4.2%
2027	3.0	4.2%
2028	3.1	4.2%
2029	3.2	4.2%
2030	3.3	4.2%

(Note: Projections from 2023 onwards are based on the estimated CAGR of 4.2% for the entire period.)

What are the Key Drivers and Restraints of the Market?

Market Drivers

• Increasing Prevalence of Hemorrhoids: Factors such as sedentary lifestyles, poor dietary habits, obesity, and pregnancy contribute to a rising incidence of hemorrhoidal conditions globally. The World Gastroenterology Organisation estimates that up to 75% of adults experience hemorrhoids at some point in their lives [1].
• Aging Global Population: The demographic shift towards an older population is a significant driver, as the risk of developing hemorrhoids increases with age due to weakened connective tissues and reduced bowel motility.
• Growing Awareness and Self-Medication: Increased public awareness regarding hemorrhoid symptoms and available treatments, coupled with the accessibility of OTC products, promotes self-medication, fueling market demand.
• Advancements in Formulations: Development of novel drug delivery systems and improved formulations offering faster relief, better efficacy, and enhanced patient compliance contributes to market growth. This includes combinations of active ingredients for multi-symptom relief.
• Expansion of E-commerce: The growing popularity of online purchasing for pharmaceutical products offers convenience and accessibility, driving sales growth through online retail channels.

Market Restraints

• Stigma and Hesitation to Seek Medical Advice: Despite increasing awareness, a social stigma associated with anal health issues can lead to delayed diagnosis and treatment, potentially limiting the immediate demand for advanced or prescription medications.
• Side Effects of Certain Medications: Some active ingredients, particularly corticosteroids and anesthetics, can cause side effects such as skin irritation, thinning of the skin, or allergic reactions, which may deter some consumers from using them regularly.
• Availability of Home Remedies and Lifestyle Modifications: Many individuals opt for home remedies or focus on lifestyle changes (e.g., increased fiber intake, hydration) as first-line treatments, potentially delaying or avoiding the purchase of medicated products.
• Stringent Regulatory Approvals for New Drugs: The process of obtaining regulatory approval for new pharmaceutical products is lengthy and costly, potentially slowing down the introduction of innovative treatments to the market.

What are the Competitive Landscape and Key Players?

The hemorrhoidal medicated market is characterized by a mix of large multinational pharmaceutical companies and smaller specialized manufacturers. Competition is primarily based on product efficacy, brand reputation, pricing, and distribution network.

Key Players include:

• Johnson & Johnson: Offers a range of OTC products under brands like Tucks and Nupercainal.
• Bayer AG: Markets products such as Preparation H and other related treatments.
• GlaxoSmithKline (GSK) plc: Known for brands like Anusol and various other topical treatments.
• Reckitt Benckiser Group plc: Has a presence with OTC hemorrhoid relief products.
• Prestige Consumer Healthcare Inc.: Holds brands like Murad and other skincare and personal care products that may include hemorrhoid treatments.
• Amor Pharmaceutical Co., Ltd.: A significant player in certain Asian markets with a portfolio of dermatological and gastrointestinal products.
• Sanofi S.A.: While not solely focused on hemorrhoids, their broader pharmaceutical portfolio may encompass relevant treatments.

The market is fragmented, with significant competition in the OTC segment. Differentiation often occurs through product innovation, such as combining multiple active ingredients or offering unique application methods.

What are the Price Projections for Hemorrhoidal Medicated Products?

The pricing of hemorrhoidal medicated products varies significantly based on formulation, active ingredients, brand, and whether the product is OTC or prescription-based.

• OTC Products: Prices for OTC creams, ointments, and suppositories typically range from $8 to $25 for a standard-sized package (e.g., 1 ounce of cream or 12 suppositories). Medicated wipes or pads may range from $6 to $15 for a pack of 20-50. Pricing is influenced by the concentration and combination of active ingredients (e.g., hydrocortisone, phenylephrine, lidocaine, witch hazel). Brands with established reputations often command a premium.
• Prescription Medications: Prescription hemorrhoid treatments, including stronger corticosteroid creams, suppositories, or oral medications, can range from $30 to $100+ per prescription, depending on the dosage, duration of treatment, and insurance coverage. The cost of prescription medications is driven by proprietary formulations, R&D investment, and market exclusivity.

Price Trend Projections (2024-2030):

The average retail price for OTC hemorrhoidal medicated products is projected to increase at a CAGR of approximately 3.0% from 2024 to 2030. This increase is attributed to rising manufacturing costs, inflation, and incremental product innovation.

Prescription medication prices are expected to see a slightly higher CAGR of 4.5% due to factors such as patent expirations for some older drugs, the introduction of newer, more targeted therapies, and the pricing strategies of pharmaceutical manufacturers.

Factors influencing price fluctuations include:

• Raw Material Costs: Fluctuations in the cost of active pharmaceutical ingredients (APIs) and excipients.
• Manufacturing Efficiency: Advancements in production technology can lead to cost reductions, though this may not always translate directly to lower consumer prices.
• Regulatory Compliance Costs: Adherence to evolving pharmaceutical manufacturing standards and regulatory requirements adds to overhead.
• Competitive Pricing Strategies: The presence of numerous OTC brands encourages competitive pricing, while prescription markets are influenced by the patent landscape and market exclusivity.
• Insurance Reimbursement Policies: For prescription drugs, payer policies significantly impact patient out-of-pocket costs and the overall market price.

What is the Regulatory Landscape?

The regulatory environment for hemorrhoidal medicated products is primarily governed by national health authorities.

• United States: The Food and Drug Administration (FDA) regulates both OTC and prescription hemorrhoid treatments. OTC products must adhere to Good Manufacturing Practices (GMP) and meet specific labeling requirements. Prescription drugs undergo a more rigorous review process, including clinical trials to demonstrate safety and efficacy. The FDA's Over-the-Counter Monograph system outlines safety and effectiveness requirements for many OTC drug categories, including those for hemorrhoids.
• European Union: The European Medicines Agency (EMA) oversees drug approvals, with national agencies within member states also playing a role. Products can be authorized centrally by the EMA or through national procedures. Regulations emphasize quality, safety, and efficacy.
• Other Regions: Similar regulatory bodies exist in Canada (Health Canada), Japan (Pharmaceuticals and Medical Devices Agency - PMDA), and other major markets, each with its own specific guidelines for drug approval and market access.

Key regulatory considerations include ingredient safety profiles, appropriate labeling for intended use and warnings, manufacturing standards, and post-market surveillance to monitor adverse events. The classification of a product as OTC or prescription-dependent is a critical regulatory distinction.

Key Takeaways

The hemorrhoidal medicated market is poised for sustained growth, driven by demographic shifts and increasing health awareness. The OTC segment will continue to lead, supported by accessibility and self-medication trends. Innovation in formulations and effective distribution strategies, particularly through online channels, will be critical for market players. While competition is robust, opportunities exist for products offering enhanced efficacy and improved patient experience. Price increases are anticipated, reflecting manufacturing costs and market dynamics for both OTC and prescription segments.

FAQs

1. What is the projected market value for hemorrhoidal medicated products in 2025? The market is projected to be approximately $2.8 billion in 2025.

2. Which formulation type holds the largest market share in the hemorrhoidal medicated products market? Topical creams and ointments represent the largest segment by volume.

3. Are there significant price differences between OTC and prescription hemorrhoid medications? Yes, prescription medications are generally more expensive, ranging from $30-$100+ per prescription compared to $8-$25 for standard OTC products.

4. What is the primary factor driving the increasing prevalence of hemorrhoids? Lifestyle-related factors such as sedentary behavior, poor diet, and obesity are primary contributors.

5. Which regulatory body in the United States oversees hemorrhoid treatments? The U.S. Food and Drug Administration (FDA) regulates these products.

Citations

[1] World Gastroenterology Organisation. (2017). Hemorrhoids fact sheet. Retrieved from https://www.worldgastroenterology.org/publications/hemorrhoids-fact-sheet